ASTM E2882-19

This document is not an ASTM standard and is intended only to provide the user of an ASTM standard an indication of what changes have been made to the previous version. Because
it may not be technically possible to adequately depict all changes accurately, ASTM recommends that users consult prior editions as appropriate. In all cases only the current version
of the standard as published by ASTM is to be considered the official document.
Designation: E2882 − 12 E2882 − 19
Standard Guide for
Analysis of Clandestine Drug Laboratory Evidence
This standard is issued under the fixed designation E2882; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope
1.1 This guidestandard is intended to be used in conjunction with the general requirements for the analysis of seized drugs
(Practices E2326, E2327, E2329, and E2549; Guides E2548 and E2329). This guidestandard provides guidance on the chemical
analysis of items and samples related to suspected clandestine drug laboratories. It does not address scene attendance or scene
processing. This documentThis standard provides general guidance for the analysis of clandestine drug laboratory evidence and
is not a substitute for detailed and validated laboratory policies and technical procedures.
1.2 This guide does not replace knowledge, skill, ability, experience, education, or training and should standard cannot replace
knowledge, skills, or abilities acquired through education, training, and experience (see Practice E2326) and is to be used in
conjunction with professional judgment.judgment by individuals with such discipline-specific knowledge, skills, and abilities.
1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility
of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of
regulatory limitations prior to use.
1.4 This international standard was developed in accordance with internationally recognized principles on standardization
established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued
by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
2. Referenced Documents
2.1 ASTM Standards:
D6161 Terminology Used for Microfiltration, Ultrafiltration, Nanofiltration, and Reverse Osmosis Membrane Processes
E1605 Terminology Relating to Lead in Buildings
E2326 Practice for Education and Training of Seized-Drug Analysts
E2327 Practice for Quality Assurance of Laboratories Performing Seized-Drug Analysis
E2329 Practice for Identification of Seized Drugs
E2363 Terminology Relating to Process Analytical Technology in the Pharmaceutical Industry
E2548 Guide for Sampling Seized Drugs for Qualitative and Quantitative Analysis
E2549 Practice for Validation of Seized-Drug Analytical Methods
F2725 Guide for European Union’s Registration, Evaluation, and Authorization of Chemicals (REACH) Supply Chain
Information Exchange
3. Terminology
3.1 Definitions of Terms Specific to This Standard:
3.1.1 capacity—capacity, n—the amount of finished product that could be produced, either in one batch or over a defined period
of time, and given a set list of variables. SWGDRUG
3.1.2 catalyst—catalyst, n—a substance whose presence initiates or changes the rate of a chemical reaction, but does not itself
enter into the reaction. D6161
3.1.3 finished product—product, n—a manufactured product ready for use. SWGDRUG
This guide is under the jurisdiction of ASTM Committee E30 on Forensic Sciences and is the direct responsibility of Subcommittee E30.01 on Criminalistics.
Current edition approved Aug. 1, 2012Aug. 1, 2019. Published September 2012August 2019. Originally approved in 2012. Last previous edition approved in 2012 as
E2882 – 12. DOI: 10.1520/E2882-12.10.1520/E2882-19.
For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM Standards
volume information, refer to the standard’s Document Summary page on the ASTM website.
Available from the Scientific Working Group for the Analysis of Seized Drugs, http://www.swgdrug.org.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
E2882 − 19
3.1.4 intermediate—intermediate, n—ubstancesubstance that is manufactured for and consumed in or used for chemical
processing to be transformed into another substance. F2725
3.1.5 reagent—reagent, n—a chemical used to react with another chemical, often to confirm or deny the presence of the second
chemical. E1605
3.1.6 yield, expected—expected, n—the quantity of material or the percentage of theoretical yield anticipated at any appropriate
phase of production based on previous laboratory, pilot scale, or manufacturing data. E2363
3.1.7 yield, theoretical—theoretical, n—the quantity that would be produced at any appropriate phase of production based upon
the quantity of material to be used, in the absence of any loss or error in actual production. E2363
4. Significance and Use
4.1 An understanding of clandestine analyst should be knowledgeable, through established laboratory training, of clandestine
drug laboratory synthetic routes and the techniques used in the analysis of related samples is considered to be fundamental to the
interpretation and reporting of results. This understanding assures that results and conclusions from methods are reliable and
analytical schemes are fit for purpose. samples. This acquired knowledge of clandestine drug laboratory samples assists the analyst
in choosing the best analytical scheme to identify reagents, precursors, intermediates, and final products.
4.2 The qualitative and quantitative analyses of clandestine drug laboratory evidence can require different approaches relative
to routine seized drug analyses. Analysts shall understand the limitations of the procedures used in their qualitative and quantitative
analyses. These include such factors as method selectivity, uncertainty, and the basis for inferences from a sample(s) to a
population.
4.3 Laboratory management shall ensure that clandestine drug laboratory synthesis and analysis training be provided through
relevant procedures, literature, and practical experience. Practical experience typically includes production, sampling and analysis
of clandestine drug laboratory training samples.
4.4 Laboratory management shall ensure that chemical safety and hygiene plans address and mitigate hazards associated with
clandestine drug laboratory evidence.
4.5 It does not address scene attendance or scene processing.
4.6 Laboratory management shall consider customer/local requirements which influence the application of these recommen-
dations.
5. Safety
5.1 This guide does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of
the user of this guide to establish appropriate safety and health practices and determine the applicability of regulatory limitations
prior to use.
5.1 Many items seized at clandestine drug laboratories maycould be intrinsically dangerous.inherently hazardous. These
maycould include items of unknown composition and chemicals that have not been fully characterized and whose specific hazards
are not known. Therefore, caution must be exercised and exercise caution as routine safety protocols may not could be
sufficient.insufficient.
5.2 The following are required in addition to the routine laboratory safety program in place for the analysis of seized drugs (see
Practice E2327, Health and Safety):):
5.2.1 Safety procedures and the use of safety and protective equipment for all staff responsible for handling items;
5.2.2 Protective breathing equipment;
5.2.3 Listings of the relevant hazards (for example, MSDS)SDS) associated with components commonly found at clandestine
drug laboratory sites and knowing what they mean; and
5.2.4 Accident prevention, emergency response procedures, and incident reporting protocols.
5.3 The handling, analysis, and storage of items seized from clandestine drug laboratories require additional procedures,
facilities and equipment (see Practice E2327, Physical Plant). ). Examples are:
5.3.1 Specialized ventilation equipment (for example, fume hoods) to prevent exposure to harmful fumes and vapors;
5.3.2 Provision of personal protective equipment such as safety glasses, chemical resistant gloves, laboratory coats, respirators,
face masks, and air monitors;
5.3.3 Maintenance of a clean, uncluttered workspace;
5.3.4 Specialized emergency equipment stations;
5.3.5 Chemical disposal and disposal, destruction facilities, and procedures; and
5.3.6 Specialized evidence receipt, storage and disposal requirements designed to mitigate expected dangers (for example,
limited sample size, proper packaging of reactive materials, use of absorbents, properly ventilated storage).
5.4 Analysts shall be aware of the hazards associated with clandestine drug laboratories samples. Examples are:
5.4.1 Extracting from strong acids and bases (for example, hydriodic acid, sodium hydroxide);
E2882 − 19
5.4.2 Handling fuming acids and bases (for example, hydrochloric acid, ammonia);
5.4.3 Poisonous gases (for example, phosphine, chlorine, hydrogen sulfide) and their potential release from evidence during
analysis;
5.4.4 Poisonous, carcinogenic, and mutagenic materials (for example, mercuric chloride, chloroform, potassium cyanide);
5.4.5 Reactive and air sensitive materials (for example, white phosphorus, lithium);
5.4.6 Potential testing incompatibilities (for example, phosphorus with Raman, color test reagents with cyanide salts,
exothermic reactions);
5.4.7 Radioactive materials (for example, thorium); and
5.4.8 Volatile and flammable solvents (for example, acetone, diethyl ether, methylated spirits).solvents).
6. Sample Section for Analysis
6.1 The primary purpose of analysis is to prove or disprove allegations of clandestine drug syntheses. Accordingly, analysts
must select items which relate to the manufacturing process.
6.2 Not all items seized at a clandestine laboratory site may need to be analyzed. It is recommended that information be shared
between the analyst and on-scene personnel to aid in sample selection.While not all-encompassing, sample selection can be based
on the observations, case scenario, and preliminary field test results of the on-scene personnel.
6.3 Items should be selected for analysis, analysis (either at the scene or from items submitted to the laboratory), based on
jurisdictional requirements, and which are likely to contain:
6.3.1 Finished product,
6.3.2 Intermediates,
6.3.3 Precursors,
6.3.4 Key reagents, and
6.3.5 Reaction mixtures.
6.4 Some of the The following types of items maycan be analyzed as they cancould assist in determining the chemical
reaction(s) undertaken and the scope of the clandestine drug laboratory:
6.4.1 Materials that appear to be waste;
6.4.2 Unlabeled materials that appear to be contaminated solvents, acids, or bases; and
6.4.3 Samples from contaminated equipment.
6.5 Items Analysis is not required on all items, particularly if collected from sealed and labeled containers that are readily
obtained from local retail stores and are sold from reputable manufacturers/distributors may not need to be analyzed, particularly
if collected from sealed and labeled containers. manufacturers/distributors. These include:
6.5.1 Solvents (for example, toluene, mineral spirits),
6.5.2 Acids (for example, hydrochloric acid, sulfuric acid), and
6.5.3 Bases (for example, sodium hydroxide, ammonia water).water),
6.5.4 Salts and precipitating agents, and
6.5.5 Concentration material, filters.
7. Analysis
7.1 Substances whose presence are reported or contribute to formulating reported conclusions shall be identified with an
adequate anal
...